title: Preclinical and clinical experiences with the role of somatostatin receptors in the treatment of pituitary adenomas.
abstract: The patho-physiological role of somatostatin receptor subtypes (sst) in neuro endocrine diseases has gained enhanced scientific interest in the past few years. The development of novel somatotropin-release inhibiting factor analogs, both sst-specific and universal ligands, seem promising as a tool to further increase fundamental insights in sst function. Eventually, this research should result in novel medical therapeutic opportunities in patients suffering from neuro-endocrine diseases. In the present review, the functional role of sst in all types of pituitary adenomas, based on recent preclinical and clinical studies, is being discussed.
authors.forename: Joost
authors.initials: J
authors.lastname: van der Hoek
authors.forename: Steven W J
authors.initials: SWJ
authors.lastname: Lamberts
authors.forename: Leo J
authors.initials: LJ
authors.lastname: Hofland
mesh_terms: D000236:Adenoma / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D010911:Pituitary Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D043562:Receptors, G-Protein-Coupled / Q000187:drug effects / Q000502:physiology; D017481:Receptors, Somatostatin / Q000187:drug effects* / Q000502:physiology; D013004:Somatostatin / Q000031:analogs & derivatives*
chemical_list: D043562:Receptors, G-Protein-Coupled; D017481:Receptors, Somatostatin; D013004:Somatostatin